Nkarta Inc. (NKTX)
2.18
-0.04 (-1.80%)
At close: Apr 23, 2025, 3:59 PM
2.21
1.21%
Pre-market: Apr 24, 2025, 04:00 AM EDT
-1.80% (1D)
| Bid | 1.65 |
| Market Cap | 154.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -108.79M |
| EPS (ttm) | -1.6 |
| PE Ratio (ttm) | -1.36 |
| Forward PE | -1.64 |
| Analyst | Buy |
| Ask | 2.3 |
| Volume | 845,866 |
| Avg. Volume (20D) | 1,444,163 |
| Open | 2.28 |
| Previous Close | 2.22 |
| Day's Range | 2.08 - 2.28 |
| 52-Week Range | 1.31 - 8.33 |
| Beta | 0.84 |
About NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 157
Stock Exchange NASDAQ
Ticker Symbol NKTX
Website https://www.nkartatx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 633.94% from the latest price.
Stock Forecasts4 weeks ago
+43.8%
Nkarta shares are trading higher after the company...
Unlock content with
Pro Subscription
8 months ago
+3.22%
Nkarta shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Raymond James upgraded the stock from Outperform to Strong Buy.
